PRACTECAL-PKPD is an exploratory pharmacokinetic and pharmacodynamic sub-study investigating
the relationship between the patients' exposure to anti- tuberculosis (TB) drugs in the
TB-PRACTECAL trial investigational regimens and their respective treatment outcomes.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Medecins Sans Frontieres, Netherlands
Collaborators:
Clinical HIV Reserach Unit, Wits Health Consortium Drugs for Neglected Diseases eResearch Technology, Inc. Global Alliance for TB Drug Development Hackensack Meridian Health Hackensack University Medical Centre Liverpool School of Tropical Medicine London School of Hygiene and Tropical Medicine London School of Hygiene and Tropical Medicine Clinical Reserach Department Ministry of Health, Belarus Ministry of Health, Republic of Uzbekistan Ministry of Public Health, Republic of Belarus Minsk Republican Research and Practical Centre for Pulmonology and Tuberculosis Swiss Tropical & Public Health Institute TB & HIV Investigative Network (THINK) THINK TB & HIV Investigative Network University College London Institute for Global Health University College, London University of California, San Francisco University of California, San Francisco (UCSF), USA University of Liverpool Wits Health Consortium (Pty) Ltd World Health Organization
Treatments:
Bedaquiline Clofazimine Diarylquinolines Linezolid Moxifloxacin Norgestimate, ethinyl estradiol drug combination